Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Patients are quietly injecting unapproved peptides like BPC-157 — and not telling their surgeons. Use of these compounds has skyrocketed 33-fold since 2020, yet none have passed rigorous human safety trials. With new HHS policy loosening compounding restrictions, orthopedic surgeons are being urged to ask every patient about peptide use before going under the knife.
Patients are showing up to pre-op appointments having injected unapproved, untested peptides — and most aren't mentioning it. Compounds like BPC-157 and TB-500 (dubbed the "Wolverine stack" on social media) are being used for tendon healing, muscle recovery, and performance enhancement, despite no approved human clinical trials. A review of 15 million patient records found 1,039 documented BPC-157 users — a number experts say vastly underestimates true prevalence, since the compound has no national drug code and never appears on medication lists.
The regulatory landscape just got murkier. In October 2026, HHS Secretary RFK Jr. announced that state-licensed pharmacies and physicians can now compound six unapproved peptides — including BPC-157 and TB-500 — without FDA enforcement action. But experts warn: a cleaner vial of an untested drug is still an untested drug. Product purity remains a serious concern, with online-sold peptides showing wide variability in content, and past compounding disasters (like the 2012 fungal meningitis outbreak) serving as cautionary tales.
Key Takeaways:
Why it matters: With peptide use surging and regulation still catching up to the science, orthopedic surgeons face real patient safety risks — from unknown sterility to potential complications — if they don't proactively screen for these compounds before surgery.
